Alpha Cognition Inc. Common Stock (ACOG:NASDAQ) closed at $8.34 on October 23, 2026, up 0.36% on the day. The stock trades 17.8% below its 52-week high of $10.14 and 85.3% above its 52-week low of $4.50. Over the past year, it gained 21.4%. Alpha Cognition Inc. Common Stock is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ACOG closed higher on 118 days (47%). Its best day was February 6, 2026 (+13.33%) and its worst was February 5, 2026 (-10.36%). The stock moved 10% or more in a single session 6 times.
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The Company's pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company's ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for traumatic brain injury. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.
Find more stocks like ACOG with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.